Novel crystal form of 2-amino-2-(2-(1-decyl-1h-1,2,3-triazol-4-yl)ethyl)propane-1,3-diol hemifumarate, and pharmaceutical composition containing same

A novel crystalline form of 2-amino-2-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)propane-1,3-diol hemifumarate addresses the stability and hygroscopicity issues of previous forms, ensuring stable and high-purity pharmaceutical production and effective treatment of multiple sclerosis and other conditions.

WO2024228436A1PCT designated stage expired Publication Date: 2024-11-07NEXTGEN BIOSCIENCE CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2023/015991
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-02
Filing Date
2023-10-17
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

The existing forms of 2-amino-2-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)propane-1,3-diol, such as its free base or hydrochloride salt, are highly hygroscopic and physically unstable, making them unsuitable for long-term storage and mass production as pharmaceuticals, while mixtures of polymorphs complicate reproducible manufacturing and stability.

Method used

Development of a novel crystalline form of 2-amino-2-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)propane-1,3-diol hemifumarate with specific X-ray powder diffraction patterns and low hygroscopicity, which maintains stability and purity during long-term storage, facilitating mass production and pharmaceutical formulation.

Benefits of technology

The novel crystalline form exhibits improved stability and low hygroscopicity, enabling stable long-term storage and high-purity production, and is effective in treating multiple sclerosis, cerebral ischemia, and other conditions without causing cardiovascular side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2023015991_07112024_PF_FP_ABST
    Figure KR2023015991_07112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a novel crystal form of a 2-amino-2-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)propane-1,3-diol hemifumarate, and a pharmaceutical composition containing same. More specifically, the present invention relates to: a novel crystal form of a 2-amino-2-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)propane-1,3-diol hemifumarate, and a pharmaceutical composition containing same, the crystal form not becoming denatured even if stored for long time, having low hygroscopicity, having, in itself, improved stability so as to enable mass production and facilitate development as drug, and being obtainable with high purity and uniform quality.
Need to check novelty before this filing date? Find Prior Art

Description

Novel crystalline form of 2-amino-2-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)propane-1,3-diol hemifumaric acid salt and pharmaceutical composition comprising the same

[0001] The present invention relates to a novel crystalline form of 2-amino-2-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)propane-1,3-diol hemifumaric acid salt and a pharmaceutical composition comprising the same. More specifically, the present invention relates to a novel crystalline form of 2-amino-2-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)propane-1,3-diol hemifumaric acid salt, which does not denature even upon long-term storage, has low hygroscopicity, and has improved stability of the crystalline form itself, thereby facilitating development as a drug while being applicable to mass production and being obtainable in a high-purity, homogeneous quality, and a pharmaceutical composition comprising the same.

[0002] The 2-amino-2-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)propane-1,3-diol compound (NXC 736; hereinafter referred to as compound 1) selectively binds to receptors of each S1P subtype and can be usefully used for the prevention or treatment of multiple sclerosis or ischemic stroke.

[0003] However, the free base of compound 1 or its hydrochloride salt had the disadvantage of being highly hygroscopic and physically unstable after exposure to high humidity conditions, and therefore, a hemifumaric acid salt of compound 1 (hereinafter referred to as compound 1a) with improved hygroscopicity and stability even during long-term storage was developed as an alternative.

[0004] Meanwhile, it is generally known that it is desirable to manufacture drugs with a uniform and defined composition. For example, using a mixture of polymorphs rather than a specific crystal form presents significant challenges. Differences in crystal structure can lead to differences in physicochemical parameters, such as stability, solubility, and bioavailability. Furthermore, mixtures of polymorphs of a compound typically exhibit different physicochemical parameters than the pure forms contained within the mixture. Furthermore, it is extremely difficult to reproducibly manufacture each batch of a polymorph mixture identically.

[0005] On the other hand, crystalline forms generally have low solubility, resulting in low bioavailability per unit weight. Therefore, to ensure stability and produce a sustained-release formulation, selecting an appropriate crystalline form must take these stability and solubility factors into account. This presents a significant challenge in drug development.

[0006] Accordingly, the inventors of the present invention have made extensive research efforts to discover a form of compound 1a that has long-term stability and can be applied industrially for pharmaceutical purposes, and as a result, they have confirmed that the crystalline form of the compound having a specific X-ray powder diffraction pattern has low hygroscopicity and is therefore advantageous for formulation, and the stability of the crystalline form itself is also very excellent and is useful for long-term storage, thereby completing the present invention.

[0007] The purpose of the present invention is to provide a novel crystalline form of 2-amino-2-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)propane-1,3-diol hemifumaric acid salt (compound 1a), which does not deteriorate even during long-term storage, has low hygroscopicity, and has improved stability of the crystalline form itself, making it easy to develop as a drug while being applicable to mass production and can be obtained in a high-purity, homogeneous quality, and a pharmaceutical composition comprising the same.

[0008] In order to solve the above problem, in one specific example of the present invention, a crystalline form A of a compound represented by the following chemical formula 1a having diffraction peaks at diffraction angles (2θ±0.2°) of 5.8°, 19.0°, 20.8°, 22.2°, and 26.4° in a powder X-ray diffraction (PXRD) pattern and a pharmaceutical composition comprising the same as an active ingredient are provided:

[0009] [Chemical Formula 1a]

[0010]

[0011] In one specific example of the present invention, the crystalline form A of compound 1a has an IR spectrum of 2924 cm -1 , 2853 cm -1 , 1629 cm -1 , 1533 cm -1 , 1355 cm -1 , 1048 cm -1 , and 808 cm -1 It has a peak at .

[0012] In one specific example of the present invention, the crystalline form A of compound 1a has a Raman spectrum of 28.1 cm -1 , 201.9 cm -1 , 949.9 cm -1 , 1209.7 cm -1 , 1311.4 cm -1 , 1366.8 cm -1 , and 1570.3 cm -1 It has a peak at .

[0013] In one specific example of the present invention, a crystalline form B of compound 1a having diffraction peaks at diffraction angles of 6.4°, 18.6°, 20.7°, 22.4°, and 29.2° (2θ±0.2°) in a powder X-ray diffraction pattern and a pharmaceutical composition comprising the same as an active ingredient are provided.

[0014] In one specific example of the present invention, the crystalline form B of compound 1a has an IR spectrum of 2918 cm -1 , 2848 cm-1 , 1629 cm -1 , 1575 cm -1 , 1355 cm -1 , 1045 cm -1 , and 814 cm -1 It has a peak at .

[0015] In one specific example of the present invention, the crystalline form B of compound 1a has a Raman spectrum of 22.3 cm -1 , 259.1 cm -1 , 939.4 cm -1 , 1204.5 cm -1 , 1331.6 cm -1 , 1575.2 cm -1 , and 2813.9 cm -1 It has a peak at .

[0016] In one specific example of the present invention, a crystalline form C of compound 1a having diffraction peaks at diffraction angles (2θ±0.2°) of 6.7°, 16.9°, 20.4°, 22.0° 23.5°, 33.0°, and 36.4° in a powder X-ray diffraction (PXRD) pattern and a pharmaceutical composition comprising the same as an active ingredient are provided.

[0017] In one specific example of the present invention, the crystalline form C of compound 1a has an IR spectrum of 2920 cm -1 , 2849 cm -1 , 1603 cm -1 , 1554 cm -1 , 1357 cm -1 , 1043 cm -1 , and 807 cm -1 It has a peak at .

[0018] In one specific example of the present invention, the crystalline form C of compound 1a has a Raman spectrum of 28.1 cm -1 , 115.4 cm -1 , 687.6 cm -1 , 976.3 cm -1 , 1204.5 cm -1 , 1368.8 cm -1, 1565.4 cm -1 , and 2818.1 cm -1 It has a peak at .

[0019] In one specific example of the present invention, a crystalline form D of compound 1a having diffraction peaks at diffraction angles (2θ±0.2°) of 5.9°, 19.0°, 22.2°, 23.0°, 26.0°, and 26.4° in a powder X-ray diffraction (PXRD) pattern and a pharmaceutical composition comprising the same as an active ingredient are provided.

[0020] In one specific example of the present invention, the crystalline form D of compound 1a has an IR spectrum of 2924 cm -1 , 2853 cm -1 , 1629 cm -1 , 1533 cm -1 , 1355 cm -1 , 1048 cm -1 , and 808 cm -1 It has a peak at .

[0021] In one specific example of the present invention, the crystalline form D of compound 1a has a Raman spectrum of 28.1 cm -1 , 201.9 cm -1 , 949.9 cm -1 , 1209.7 cm -1 , 1311.4 cm -1 , 1366.8 cm -1 , and 1570.3 cm -1 It has a peak at .

[0022]

[0023] In one specific example of the present invention, a crystalline form E of compound 1a having diffraction peaks at diffraction angles (2θ±0.2°) of 18.7°, 20.3°, 21.9°, 22.3°, 26.2°, and 28.6° in a powder X-ray diffraction (PXRD) pattern and a pharmaceutical composition comprising the same as an active ingredient are provided.

[0024] In one specific example of the present invention, the crystalline form E of compound 1a has an IR spectrum of 2924 cm-1 , 2853 cm -1 , 1639 cm -1 , 1531 cm -1 , 1354 cm -1 , 1048 cm -1 , and 808 cm -1 It has a peak at .

[0025] In one specific example of the present invention, the crystalline form E of compound 1a has a Raman spectrum of 28.1 cm -1 , 201.9 cm -1 , 944.6 cm -1 , 1311.4 cm -1 , 1366.8 cm -1 , and 1570.3 cm -1 It has a peak at .

[0026] In one specific example of the present invention, a crystalline form F of compound 1a having diffraction peaks at diffraction angles (2θ±0.2°) of 18.6°, 19.2°, 20.8°, 25.7°, 29.2°, 31.0°, 32.1°, and 33.9° in a powder X-ray diffraction (PXRD) pattern and a pharmaceutical composition comprising the same as an active ingredient are provided.

[0027] In one specific example of the present invention, the crystalline form F of compound 1a has an IR spectrum of 2918 cm -1 , 2849 cm -1 , 1629 cm -1 , 1575 cm -1 , 1355 cm -1 , 1045 cm -1 , and 814 cm -1 It has a peak at .

[0028] In one specific example of the present invention, the crystalline form F of compound 1a has a Raman spectrum of 22.3 cm -1 , 259.1 cm -1 , 939.4 cm -1 , 1204.5 cm -1 , 1331.6 cm -1 , 1575.2 cm-1 , and 2813.9 cm -1 It has a peak at .

[0029] In one specific example of the present invention, a crystalline form G of compound 1a having diffraction peaks at diffraction angles (2θ±0.2°) of 8.2°, 18.8°, 20.4°, 22.0°, 24.6°, 26.3°, and 28.7° in a powder X-ray diffraction (PXRD) pattern and a pharmaceutical composition comprising the same as an active ingredient are provided.

[0030] In one specific example of the present invention, the crystalline form G of compound 1a has an IR spectrum of 2924 cm -1 , 2853 cm -1 , 1639 cm -1 , 1531 cm -1 , 1354 cm -1 , 1048 cm -1 , and 808 cm -1 It has a peak at .

[0031] In one specific example of the present invention, the crystalline form G of compound 1a has a Raman spectrum of 28.1 cm -1 , 201.9 cm -1 , 944.6 cm -1 , 1311.4 cm -1 , 1366.8 cm -1 , and 1570.3 cm -1 It has a peak at .

[0032] In one specific example of the present invention, crystalline form F of compound 1a exhibits a moisture adsorption rate of 0.02% under 90% RH conditions as a result of DVS evaluation.

[0033] In one specific example of the present invention, crystalline form G of compound 1a exhibits a moisture adsorption rate of 0.04% under 90% RH conditions as a result of DVS evaluation.

[0034] The novel crystalline form of compound 1a according to the present invention has lower hygroscopicity compared to the existing salt and amorphous form of compound 1, and the stability of the crystalline form itself is improved, so that it can be stably maintained over the long term without changes in content or increases in impurities.

[0035] The novel crystalline form of compound 1a according to the present invention can be obtained as a high-purity raw material, and has the advantage of maintaining high purity for a long period of time due to a significantly low increase in volatile substances even during long-term storage, and exhibiting low hygroscopicity within a range of relative humidity. Therefore, it is very advantageous in the processing and storage of pharmaceuticals, facilitating formulation, and after manufacturing a formulation containing it, the same state is maintained, so that the content uniformity of the formulation can be stably maintained for a long period of time, making it easily applicable to mass production.

[0036] In one specific example of the present invention, the novel crystalline form of compound 1a according to the present invention and a pharmaceutical composition comprising the same as an active ingredient can be usefully used for the prevention or treatment of multiple sclerosis, ischemic stroke, focal segmental glomerulosclerosis (FSGS), inflammatory bowel disease, interstitial fibrosis and tubular atrophy (IFTA), or alopecia areata (AA).

[0037] In one specific example of the present invention, the inflammatory bowel disease may be ulcerative colitis (UC) or Crohn's disease (CD).

[0038] In one specific example of the present invention, the pharmaceutical composition may be a pharmaceutical composition that does not cause cardiovascular disease side effects.

[0039] Among the above-mentioned medicinal uses, the pharmacological effects related to multiple sclerosis and cerebral ischemia are described in Korean Patent (KR) Registration No. 10-1830244, and the pharmacological effects for other medicinal uses are described below.

[0040] The novel crystalline form of compound 1a of the present invention was confirmed to exhibit immunosuppressive action when administered orally to mice and rats, and showed excellent antifibrotic effects in the UUO (Unilateral Urinary Obstruction) renal fibrosis model and the adenine-induced renal fibrosis model, and therefore can be usefully used as an active ingredient of a pharmaceutical composition capable of preventing or treating multiple sclerosis, cerebral ischemia, focal segmental glomerulosclerosis, inflammatory bowel disease, interstitial fibrosis and tubular atrophy, or alopecia areata.

[0041] In one specific embodiment of the present invention, the pharmaceutical composition of the present invention may further comprise one or more pharmaceutically acceptable carriers in addition to the novel crystalline form of compound 1a, which is an active ingredient, for administration. Pharmaceutically acceptable carriers may include saline solution, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and mixtures of one or more of these components. If necessary, other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate the composition into an injectable formulation such as an aqueous solution, suspension, or emulsion, or into a pill, capsule, granule, or tablet. Accordingly, the composition of the present invention may be a patch, a liquid, a pill, a capsule, a granule, a tablet, a suppository, or the like. These preparations can be prepared by conventional methods used in formulation in the art or by methods disclosed in Remington's Pharmaceutical Science (latest edition), Mack Publishing Company, Easton PA, and can be formulated into various preparations depending on each disease or ingredient.

[0042] In one specific example of the present invention, the pharmaceutical composition of the present invention may be administered orally or parenterally, for example, intravenously, subcutaneously, intraperitoneally, or topically, depending on the intended method, and the dosage may vary depending on the patient's weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of the disease.

[0043] In one embodiment of the present invention, a method for treating multiple sclerosis, cerebral ischemia, focal segmental glomerulosclerosis, inflammatory bowel disease, interstitial fibrosis and tubular atrophy or alopecia areata is provided, comprising administering to a subject a pharmaceutically effective amount of a novel crystalline form of compound 1a according to the present invention.

[0044] In one embodiment of the present invention, the use of the novel crystalline form of compound 1a according to the present invention is provided in the manufacture of a medicament for the treatment of multiple sclerosis, cerebral ischemia, focal segmental glomerulosclerosis, inflammatory bowel disease, interstitial fibrosis and tubular atrophy or alopecia areata.

[0045] The novel crystalline form of 2-amino-2-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)propane-1,3-diol hemifumaric acid salt (compound 1a) according to the present invention is advantageous in that it does not denature even upon long-term storage compared to the amorphous form, has low hygroscopicity, and has improved stability of the crystalline form itself, making it easy to develop as a drug while being applicable to mass production and being obtainable in a high-purity, homogeneous quality, and the pharmaceutical composition of the present invention containing the crystalline form as an active ingredient can be usefully used for the prevention or treatment of multiple sclerosis, cerebral ischemia, focal segmental glomerulosclerosis, inflammatory bowel disease, interstitial fibrosis and tubular atrophy, or alopecia areata.

[0046] Figure 1 is a powder X-ray diffraction (PXRD) graph showing the powder X-ray diffraction patterns of crystalline forms A (GVK form A) and D (GVK form D) of compound 1a.

[0047] Figure 2 is a powder X-ray diffraction (PXRD) graph showing the powder X-ray diffraction patterns of crystalline forms F (Sundia form 3) and B (GVK form B) of compound 1a.

[0048] Figure 3 is a powder X-ray diffraction (PXRD) graph showing the crystalline forms G (Yuhan form 1) and E (Sundia form 1) of compound 1a.

[0049] Figure 4 is a powder X-ray diffraction (PXRD) graph showing the powder X-ray diffraction pattern of crystalline form C (GVK form C) of compound 1a.

[0050] Figure 5 is IR spectrum data of crystalline form G of compound 1a.

[0051] Figure 6 shows Raman spectrum data of crystalline forms G (Yuhan form 1) and E (Sundia form 1) of compound 1a.

[0052] Figure 7 shows the DVS measurement results of crystalline form G (Yuhan form 1) of compound 1a.

[0053] Figure 8 is a graph showing changes in the number of total T cells and T cell subtypes in mice after oral administration of compound 1a (crystalline form G; 3 mg / kg / day).

[0054] Figure 9 is a graph showing changes in the number of total T cells and T cell subtypes in rats after oral administration of compound 1a (crystalline form G; 10 mg / kg / day).

[0055] Figure 10 is a graph showing the effect of compound 1a (crystalline form G; 5, 10 mg / kg / day) on suppressing inflammatory bowel disease in a DSS-induced colitis mouse model.

[0056] Figure 11 is a table showing the evaluation test of the effect of compound 1a (crystalline form G; 1, 3, 10, 30 μM) on HEK293 cells in which the hERG gene is overexpressed.

[0057] Figure 12 is a graph showing the results of measuring heart rate in a beagle dog after oral administration of compound 1a (crystalline form G; 12.5, 25, 50 mg / kg).

[0058] Figure 13 is a graph showing the effect of compound 1a (crystalline form G; 10, 30, 90 mg / kg / day) on renal fibrosis in the UUO mouse model.

[0059] Figure 14 is a graph showing the effect of compound 1a (crystalline form G; 10, 30, 90 mg / kg / day) on renal fibrosis in an adenine-induced CKD mouse model.

[0060] Figure 15 shows the results of measuring the AA lesion area after oral administration of 30 mg / kg of compound 1a (crystalline form G) for 12 weeks to 10-16 week old C3H / HeJ mice that were induced with alopecia areata.

[0061] Figure 16 shows the results of measuring the disease-free ratio after oral administration of 30 mg / kg of compound 1a (crystalline form G) for 12 weeks to 10-16 week old C3H / HeJ mice with alopecia areata.

[0062] Figure 17 is a photograph comparing the induction of alopecia areata after administering compound 1a (crystalline form G) to 10-16 week old C3H / HeJ mice that were induced to have alopecia areata.

[0063] General definitions and terms

[0064] Unless otherwise specifically defined, ratios (including percentages) or portions herein are calculated by weight.

[0065] The expressions "comprise" or their synonyms "contains", "includes" or "has" as used in the present invention are open-ended and do not exclude other unrecited elements, steps or components.

[0066] The use of the term "about" encompasses and describes a value or parameter per se. For example, "about x" encompasses and describes "x" itself. In some embodiments, the term "about" used in connection with measurement or defining a value, unit, constant, or range of values, unless otherwise indicated, refers to a variation of ±1% to ±10%. For example, in some embodiments, "about 82°C" encompasses 82°C to 83°C.

[0067] The term "pharmaceutical composition" refers to an active ingredient, optionally combined with one or more pharmaceutically acceptable ingredients (e.g., without limitation, carriers and / or excipients). The active ingredient is exemplified by a compound of formula I or a hemifumarate thereof, one or more crystalline forms according to the invention, or one or more crystalline compositions according to the invention.

[0068] The terms "administration" or "administering" refer to methods that enable delivery of a compound or composition to the site of its desired biological action. Such methods include, but are not limited to, oral, parenteral (including intravenous, subcutaneous, intraperitoneal, intramuscular, and intravascular injection or infusion), topical, and rectal administration.

[0069] In pharmaceutical or pharmacologically active agents, the term "effective amount" refers to an amount of a drug or agent that is sufficient to achieve the desired effect without being toxic. In the context of oral dosage forms herein, the "effective amount" of an active ingredient in a composition refers to the amount required to achieve the desired effect, together with another active ingredient in the composition. The effective amount can be determined individually and may vary depending on the recipient, the age of the specific active ingredient, and general conditions. In specific cases, the effective amount can be determined by those skilled in the art through routine testing.

[0070] The terms "active ingredient," "therapeutic agent," "active substance," or "active agent" refer to a chemical entity useful for effectively treating or preventing a target disorder, disease, or condition. As used herein, these terms may refer to, for example, a compound of formula I or a hemifumarate thereof, one or more crystalline forms according to the invention, or one or more crystalline compositions according to the invention.

[0071] The term "hygroscopicity" used in the present invention means a property of a material not to absorb or adsorb moisture in the air, and is a concept contrasting with hygroscopicity, which is a property of a material to attract and retain water molecules from its surrounding environment.

[0072] The term "stability" used in the present invention is a term indicating the degree to which the salt of the compound represented by Chemical Formula 1 of the present invention or the composition containing the same is chemically or physically stable for a specific condition and time. The purpose of the stability test is to provide a basis for how the quality of the salt of the present invention changes over time under the influence of various environmental factors such as temperature, humidity, and light, and to establish the period of use (or expiration date) and recommended storage conditions of the finished pharmaceutical product when manufacturing a pharmaceutical product using the same in the future.

[0073] According to the stability test standards for pharmaceuticals, etc. according to the notice of the Ministry of Food and Drug Safety of the Republic of Korea, a "severe test" is stipulated to confirm the decomposition process and decomposition products of pharmaceuticals, etc. under harsh conditions, and as the test conditions, the conditions of light, temperature, and humidity are set in consideration of the characteristics of the sample. However, if the sample is a raw material, the test conditions in an aqueous solution state are included, and the effects of oxidation and photodegradation on the raw pharmaceutical material and the sensitivity to hydrolysis according to the pH value range are evaluated. Accordingly, a stability evaluation was performed on the novel crystalline form of compound 1a.

[0074] In an X-ray powder diffraction (PXRD or XRD) spectrum, the diffraction pattern obtained from a crystalline compound is generally characteristic for a particular crystal form, where the relative intensities of the bands (especially at low angles) can vary depending on orientation effects prevailing due to differences in crystallization conditions, particle diameter, and other measurement conditions. Therefore, the relative intensities of the diffraction peaks are not characteristic for a given crystal form. When determining whether a crystal form is the same as one known in the art, it is more important to note the relative positions of the peaks than their relative intensities. Furthermore, it is well known in the art that there can be some error in the peak positions for any given crystal form. For example, the positions of peaks can shift during sample analysis due to changes in temperature, sample movement, or instrument calibration; the measurement error in the 2θ value can sometimes be about ±0.2°, typically about ±0.1°. Therefore, when determining the crystal structure, these errors must be taken into account. If the crystal form according to the present invention is substantially as depicted in the drawings, the term "substantially" is also intended to include such differences in diffraction peaks.

[0075] In a PXRD pattern, peak positions are usually expressed in terms of the angle 2θ or the crystal surface distance d, and a simple conversion between d and θ is d = λ / 2sinθ, where d represents the crystal surface distance, λ represents the wavelength of the incident X-ray, and θ is the diffraction angle. For the same crystalline form of the same compound, the peak positions of the PXRD pattern are generally similar, and the relative intensity error can be large. It should also be noted that in the identification of mixtures, some diffraction lines may disappear due to factors such as content reduction, and therefore it is not necessary to rely on all the bands observed in a high-purity sample, and even one band may be characteristic for a given crystal.

[0076] Differential scanning calorimetry (DSC) is used to measure the transition temperatures at which a crystal absorbs or releases heat due to changes in its crystal structure or during crystal melting. The error in thermal transition temperature and melting point is typically within about 5°C, and generally within about 3°C, for the same crystalline form of the same compound in successive analyses. When a compound is described as having a given DSC peak or melting point, this means that the DSC peak or melting point is ±5°C. An auxiliary method using DSC is provided to identify different crystalline forms. Different crystalline forms can be identified based on their different transition temperature characteristics. The DSC peak or melting point of a mixture can vary over a wide range. Furthermore, the melting point is related to the rate of temperature rise due to decomposition during melting of a substance.

[0077] Dynamic Vapor Sorption (DVS) is a method that has been used for a long time to investigate the interaction between active pharmaceutical ingredients (APIs) and pharmaceutical preparations and moisture. The measurement is performed by exposing the sample to a desired relative humidity until the weight change of the sample stabilizes using a DVS moisture sorption equipment (hygroscopicity analysis device) to analyze the moisture absorption rate of the sample at a specific temperature.

[0078] Sphingosine-1-phosphate (S1P) receptors 1-5 constitute a family of G protein-coupled receptors with seven transmembrane domains. These receptors, designated S1P1 to S1P5, are activated through binding to sphingosine-1-phosphate, which is generated by sphingosine kinase-catalyzed phosphorylation of sphingosine. S1P1, S1P4, and S1P5 receptors activate Gi but not Gq, whereas S1P2 and S1P3 receptors activate both Gi and Gq. S1P3 receptors respond to agonists in response to increases in intracellular calcium, whereas S1P1 receptors do not.

[0079] The 2-amino-2-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)propane-1,3-diol compound (hereinafter referred to as compound 1) selectively binds to each receptor of the S1P subtype and acts as a functional antagonist to reduce lymphocytes in the peripheral bloodstream.

[0080] Compound 1 is useful for the treatment of multiple sclerosis and cerebral ischemia, see Korean Patent Publication No. 10-2017-0087813, incorporated herein by reference.

[0081] Meanwhile, inflammatory bowel disease (IBD) is a chronic condition characterized by recurring abnormal inflammation within the intestines. It is caused by an immune response to intestinal flora, and the most common types are ulcerative colitis and Crohn's disease. It primarily affects Westerners, but the number of patients in Korea is increasing as the Asian diet becomes more Westernized. Ulcerative colitis was once highly prevalent in Europe and North America, where meat consumption is a major factor, but recently, due to Westernized eating habits, its incidence has been increasing in East Asia, including Korea. Crohn's disease is a chronic inflammatory bowel disease that can occur anywhere in the digestive tract, from the mouth to the anus. Currently, there is no drug treatment that can completely cure ulcerative colitis.

[0082] Furthermore, worldwide, organ transplants increased by 5.8% year-on-year to approximately 120,700 in 2015, with approximately 60% of these being kidney transplants. Interstitial fibrosis and tubular atrophy (IFTA) develops in approximately 25% of patients one year after kidney transplantation. Histopathological changes in the transplanted kidney cause the interstitial space to expand and replace normal tissue, leading to tubular atrophy and interstitial fibrosis, which in turn leads to a decrease in glomerular filtration rate and increased proteinuria. The incidence of IFTA is 66% at 5 years after transplantation and 90% at 10 years. Initially, these symptoms are primarily due to immunological causes, but later on, they are primarily attributed to the toxicity of immunosuppressants, such as calcineurin inhibitors.

[0083] The IFTA-inducing mechanism of calcineurin inhibitors, which are mainly used as maintenance immunosuppression after transplantation, is not clear, but they are known to cause fibrosis by inducing vasoconstriction, oxidative stress, and TGF-β.

[0084] Currently, in addition to calcineurin inhibitors, anti-metabolites, and steroid combination therapy are used for chronic transplant rejection, but there is no clearly established treatment method for IFTA. Therefore, if a drug that exhibits both immunosuppressive and anti-fibrotic effects is developed, it is expected that the quality of life of patients after transplantation can be improved.

[0085] Focal segmental glomerular sclerosis (FSGS) is a filtration disorder and proteinuria caused by structural damage (e.g., sclerosis) to glomerular podocytes, the kidney's filtration system. It is the most common cause of end-stage renal disease. Approximately 300,000 patients worldwide, with approximately 80,000 in the United States, accounting for one-third of all adult nephrotic syndrome cases. Currently, steroids, immunosuppressants, and angiotensin receptor blockers are used, but they can cause serious complications such as renal failure and anemia. Therefore, there is a need to develop drugs with improved side effects and efficacy compared to existing FSGS treatments.

[0086] Alopecia areata is a condition in which hair loss occurs in circular patterns. It can occur in one or two circular patches, or in severe cases, multiple patches can occur simultaneously. The areas of hair loss can coalesce, and hair loss can include eyebrows and beard hair as well as the scalp. Hair loss across the entire scalp is called alopecia totalis, while hair loss across the entire body is called alopecia universalis. Alopecia areata occurs in a band-like pattern around the temples and back of the head, called serpiginous alopecia areata. Alopecia areata is an autoimmune disease in which the immune system alters, causing immune cells to attack hair follicles and inflame them. It is believed to be caused by stress and genetics. Less than 10% of alopecia areata patients may also have other autoimmune diseases, such as atopic dermatitis, thyroid disease, and pernicious anemia. While it can affect both men and women and all ages, it is most common in children and young adults, with a prevalence of approximately 1-2% in the general population.

[0087] The most common treatment for alopecia areata is steroids. Steroid injections, oral steroids, and immunosuppressants are recognized and used as treatments. However, long-term treatment can initially show some effectiveness but can worsen or cause significant side effects such as dermatitis, scalp depression, high blood pressure, weight gain, heartburn, and gastritis, and can lead to relapse. Currently, the oral JAK inhibitor Olumiant (ingredient name: Baricitinib), known as a treatment for rheumatoid arthritis, received approval from the U.S. Food and Drug Administration (FDA) in June 2022 as the first systemic treatment for alopecia areata. Following this, Pfizer, the world's leading pharmaceutical company, announced similar efficacy data to Olumiant after completing a phase 3 trial of PF-06651600 (ingredient name: Ritlecitinib), a type of JAK inhibitor. Notably, Pfizer did not observe major adverse cardiac events (MACE) or infectious side effects, which are concerns with long-term administration of JAK inhibitors. Based on these results, Pfizer applied for marketing approval to the FDA. Accordingly, there is a continuous demand for the development of drugs that are highly effective in treating alopecia areata and are safe in terms of side effects and toxicity.

[0088] Compound 1a and its novel crystalline form according to the present invention specifically bind to S1PR1 and S1PR4 receptors and act as a functional antagonist, thereby not causing cardiovascular disease side effects due to non-selectivity for S1PR subtypes, and at the same time, have effects of preventing and treating focal segmental glomerulosclerosis, preventing and treating interstitial fibrosis and tubular atrophy, preventing or treating inflammatory bowel disease, and preventing or treating alopecia areata.

[0089]

[0090] Hereinafter, the present invention will be described in more detail through examples. However, the following examples are intended to further illustrate the present invention, and the scope of the present invention is not limited by these examples. Those skilled in the art may appropriately modify or alter the following examples within the scope of the present invention.

[0091]

[0092] Example: Preparation of crystalline form of hemifumaric acid salt of 2-amino-2-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)propane-1,3-diol (compound 1)

[0093]

[0094] 98 mg (0.55 times the amount) of fumaric acid and 500 mg of the free base of compound 1 were added to 25 mL of MIBK (Methyl Isobutyl Ketone) (23.9 mg / mL) and mixed with stirring at room temperature for 5 minutes. The suspension underwent the following cooling crystallization process. First, the suspension was heated to 40°C for 10 hours and then stirred at 5°C for 12 hours. Upon completion of the reaction, a thick white suspension was formed. The solid material of the suspension was centrifuged to separate the precipitate and dried under vacuum (-700 mm Hg) at room temperature for 16 hours, yielding 525.5 mg (89.2%) of the final product:

[0095] 1 H-NMR (DMSO-d6): δ 0.8 (3H, t), 1.2 (15H, m), 1.75 (4H, m), 2.65 (2H, m), 3.4 (4H, t), 4.25 (2H, t), 6.4 (1H, m), 7.8 (1H, s)

[0096] Above 1 The number of protons (based on the integrated number) of the >CH protons constituting fumaric acid appearing at δ 6.4 ppm in the H-NMR data was calculated to be half the number of protons of the corresponding free base, confirming that the salt formation composition ratio of the final product was 1:0.5.

[0097] The hemifumaric acid salt prepared as described above was recrystallized using various solvents (e.g., n-butanol, acetone, acetonitrile, methyl-t-butyl ether, methyl isobutyl ketone, etc.) and conditions to obtain crystalline forms A to G.

[0098]

[0099] Experimental Example 1: PXRD

[0100] PXRD measurements were performed using a high-power X-ray diffractometer (SmartLab, 9 kW, Rigaku). SC-70 was used as the detector. The scan range was 5.00 - 90.00 deg, the scan interval was set to 0.0200 deg, and the scan speed was set to 5.0818. The X-ray intensity was set to 45 kV, 200 mA, and the wavelength condition was set to CuKa1 / 1.540593A. The receiving parallel slit and the incident parallel slit were Soller_slit_5.0 deg, and receiving slit # 1 and 2 used 20.000 mm and 20.100 mm, respectively. The data according to the analysis are provided as 2-theta, Degree (ang.), Height (cps), FWHM (deg), Size (ang.), Int. I (cps deg).

[0101] As described above, crystalline forms A to G of compound 1a were obtained, and the peak data and graphs of the diffraction angle (2θ±0.2°) appearing in the powder X-ray diffraction spectrogram (PXRD) pattern of each crystalline form are shown below and in Figures 1 to 7:

[0102] Crystalline A: 5.8°, 19.0°, 20.8°, 22.2°, and 26.4°;

[0103] Crystalline B: 6.4°, 18.6°, 20.7°, 22.4°, and 29.2°;

[0104] Crystalline C: 6.7°, 16.9°, 20.4°, 22.0° 23.5°, 33.0° and 36.4°;

[0105] Crystalline D: 5.9°, 19.0°, 22.2°, 23.0°, 26.0°, and 26.4°;

[0106] Crystalline E: 18.7°, 20.3°, 21.9°, 22.3°, 26.2°, and 28.6°;

[0107] Crystalline F: 18.6°, 19.2°, 20.8°, 25.7°, 29.2°, 31.0°, 32.1°, and 33.9°; and

[0108] Crystalline G: 8.2°, 18.8°, 20.4°, 22.0°, 24.6°, 26.3°, and 28.7°.

[0109]

[0110] Experimental Example 2: FT-IR

[0111] Crystalline forms A~G were analyzed using a Fourier transform infrared spectrometer (Cary670, Agilent). The measurement range was approximately 500 cm -1 From 4000cm -1 It was set to . The equipment's interferometer type used was a 57 mm dynamically aligned, 60° air bearing Michelson. The measurable spectral range of the equipment was 9,000 cm. -1 corresponds to . The spectral resolution of the equipment is 0.06 cm -1 The signal-to-noise ratio is 200,000:1. The detector of the equipment used MCT, Peltier Cooled DTGS. The main IR peaks of crystal types A~G (cm -1 ) are as follows:

[0112] Crystalline A: 2924 cm -1 , 2853 cm -1 , 1629 cm -1 , 1533 cm-1 , 1355 cm -1 , 1048 cm -1 , and 808 cm -1 ;

[0113] Crystalline B: 2918 cm -1 , 2848 cm -1 , 1629 cm -1 , 1575 cm -1 , 1355 cm -1 , 1045 cm -1 , and 814 cm -1 ;

[0114] Crystalline C: 2920 cm -1 , 2849 cm -1 , 1603 cm -1 , 1554 cm -1 , 1357 cm -1 , 1043 cm -1 , and 807 cm -1 ;

[0115] Crystalline D: 2924 cm -1 , 2853 cm -1 , 1629 cm -1 , 1533 cm -1 , 1355 cm -1 , 1048 cm -1 , and 808 cm -1 ;

[0116] Crystalline E: 2924 cm -1 , 2853 cm -1 , 1639 cm -1 , 1531 cm -1 , 1354 cm -1 , 1048 cm -1 , and 808 cm -1 ;

[0117] Crystalline F: 2918 cm -1 , 2849 cm -1 , 1629 cm -1 , 1575 cm -1 , 1355 cm -1 , 1045 cm -1 , and 814 cm-1 ; and

[0118] Crystalline G: 2924 cm -1 , 2853 cm -1 , 1639 cm -1 , 1531 cm -1 , 1354 cm -1 , 1048 cm -1 , and 808 cm -1 .

[0119]

[0120] Experimental Example 3: Raman

[0121] Crystalline forms A–G were analyzed using a random scanning confocal Raman microscope (RAMANwalk, Nanophoton). The analytical conditions of the test equipment are as follows:

[0122] Excitation wavelength: 532.07 nm

[0123] Laser current: 100%

[0124] Excitation power: 20.47 mV

[0125] Excitation power density: 9.82E+05 W / cm 2

[0126] ND filter: 80.29% (200 / 255)

[0127] Grating: 300 gr / mm

[0128] Silt width: 50 μm

[0129] Exposure time: 1 second

[0130] Averaging: 10

[0131] Readout speed: 1.48 MHz

[0132] Gain: 4X

[0133] Readout port: Low noise

[0134] CCD temperature: -50 ℃

[0135] Objective lens: TU Plan ELWD 20x / NA 0.40

[0136] Measurement mode: Point

[0137] The main peaks (cm) of the Raman spectral patterns of crystal forms A~G -1 ) are as follows:

[0138] Crystalline A: 28.1 cm -1 , 201.9 cm -1 , 949.9 cm -1 , 1209.7 cm -1 , 1311.4 cm -1 , 1366.8 cm -1 , and 1570.3 cm -1 ;

[0139] Crystalline B: 22.3 cm -1 , 259.1 cm -1 , 939.4 cm -1 , 1204.5 cm -1 , 1331.6 cm -1 , 1575.2 cm -1 , and 2813.9 cm -1 ;

[0140] Crystalline C: 28.1 cm -1 , 115.4 cm -1 , 687.6 cm -1 , 976.3 cm -1 , 1204.5 cm -1 , 1368.8 cm -1 , 1565.4 cm -1 , and 2818.1 cm -1 ;

[0141] Crystal D: 28.1 cm -1 , 201.9 cm -1 , 949.9 cm -1 , 1209.7 cm -1 , 1311.4 cm -1 , 1366.8 cm-1 , and 1570.3 cm -1 ;

[0142] Crystalline E: 28.1 cm -1 , 201.9 cm -1 , 944.6 cm -1 , 1311.4 cm -1 , 1366.8 cm -1 , and 1570.3 cm -1 ;

[0143] Crystalline F: 22.3 cm -1 , 259.1 cm -1 , 939.4 cm -1 , 1204.5 cm -1 , 1331.6 cm -1 , 1575.2 cm -1 , and 2813.9 cm -1 ; and

[0144] Crystalline G: 28.1 cm -1 , 201.9 cm -1 , 944.6 cm -1 , 1311.4 cm -1 , 1366.8 cm -1 , and 1570.3 cm -1 .

[0145]

[0146] Experimental Example 4: Particle Size Distribution Measurement

[0147]

[0148] *Crystal types A~G were analyzed using a laser diffraction particle sizer (Mastersizer 3000 Aero S, Malvern), and the D50 measurement results are shown in Table 1. Manual measurement setting conditions are as follows:

[0149] Master sizer 3000 version: v3.81

[0150] Particle type: non-spherical

[0151] Particle refractive index: 1.530

[0152] Particle absorption index: 0.100

[0153] Dispersant name: dry

[0154] Dispersant refractive name: 1.000

[0155] Scattering model: Mie

[0156] Analysis model: general purpose

[0157] Laser obscuration: 0.5~8%

[0158] Trial: triplicate, averaged

[0159]

[0160] Experimental Example 5: Melting Point Measurement

[0161] The melting points of crystalline forms A to G were measured using differential scanning calorimetry (DSC) and are shown in Table 1. The error range is typically about 5 °C, and generally about 3 °C, for the same crystalline form of the same compound in successive analyses.

[0162]

[0163] Experimental Example 6: Hygroscopicity Test

[0164] The hygroscopicity test was conducted at a temperature of 25℃, and pre-drying was performed for 1 hour at a relative humidity of 0% before the test. After drying, the humidity was increased in steps of 15%, 30%, 60%, 80%, and 90%, and the mass change was observed. When the condition of dm / dt 0.002 % / min was satisfied, the next relative humidity step was moved to and the mass change according to the relative humidity was observed. If the above condition was not satisfied, the relative humidity condition was maintained for up to 6 hours and then the test was performed.

[0165] The results of DVS analysis under conditions of 90% relative humidity are shown in Table 1 below, and the results of DVS analysis of double-crystalline G are shown in Fig. 7.

[0166] For reference, the DVS analysis results of the hydrochloride salt of compound 1 showed that the compound exhibited a water adsorption rate of 49.5% under 90% RH conditions and was found to be deliquescent in nature. On the other hand, crystalline forms A to G were confirmed to have excellent low hygroscopicity, with water adsorption rates of 0.02% to 10.4% under 90% RH conditions as a result of the DVS evaluation. In particular, crystalline forms F and G showed excellent low hygroscopicity, with water adsorption rates of 0.02% and 0.04%, respectively, under 90% RH conditions as a result of the DVS evaluation.

[0167] Crystal FormNameAdsorption Rate (DVS)Particle Size / Crystal ShapeMelting PointAGVKform A8.4%D502.06±0.1Circular with rounded corners133.8℃BGVKform B0.3%D504.56±0.08Plate-like85.3℃133.8℃CGVKform C0.7%D5018.7±0.66Plate-like110.4℃DGVKform D10.4%D502.33±0.09Circular with rounded corners134.3℃ESundiaform 10.06%D5019.1±2.94Plate-like139.5℃FSundiaform 30.02%D506.54±0.17Plate-like85℃, 133℃GYunhanform 10.04%D5020±3.97 plate type 139.8℃

[0168] Experimental Example 7: Stability Study

[0169] The stability of crystalline forms A to G of compound 1a was confirmed under various conditions, including long-term conditions, harsh conditions, and physical crushing for 4 weeks.

[0170] The stability of the crystalline compound was investigated under conditions of 40°C / 75±5% RH. Physical stability was confirmed through comparative PXRD analysis before and after the test, and chemical stability was confirmed by HPLC. The experimental conditions and test results used in the stability test for crystalline forms A through G of compound 1a are as follows.

[0171]

[0172] Stability conditions and test methods:

[0173] 40℃ / 75±5% RH: Conditions when the vial is opened and held upright

[0174] The required amount (~1 mg) of solid material was dissolved in 1 mL of diluent (1:1 methanol / water), and the prepared solution was analyzed by HPLC.

[0175]

[0176] For reference, the hydrochloride salt of compound 1 changed to a liquid phase considered physically unstable after one week under high-humidity conditions (40°C / 75±5% RH), and some samples exhibited decomposition. However, according to Table 2 below, in the case of crystalline forms A to G of compound 1a, the crystalline form was maintained even after 2 to 4 weeks under high-humidity conditions (40°C / 75±5% RH), and the purity was maintained at over 99%, indicating excellent stability.

[0177] Crystalline A, Crystalline B, Crystalline C, Crystalline D, Crystalline E, Crystalline F, Crystalline G, Long-term conditions, 4-time point pattern change, no change, no change, no change, no change, no change, harsh conditions, 4-time point pattern change, no change, no change, no change, no change, no change, physical crushing, no change, no change, no change, no change, no change, no change

[0178] Experimental Example 8: Inhibitory Effect on Mouse Immune Cells FTY720 (Fingolimod) is a multiple sclerosis treatment agent that has a mechanism of action that reversibly captures a portion of lymphocytes in lymph nodes or bone marrow, thereby sequestering them in secondary lymphoid organs and inhibiting their entry into the central nervous system, or reduces the number of activated lymphocytes reaching the brain by reducing the number of lymphocytes circulating in the bloodstream.

[0179] To determine whether compound 1 (NXC 736), which acts on the S1P receptor, exhibits an effect on lymphocyte reduction, the effect of compound 1 on immune cells was evaluated. After oral administration of compound 1 at 3 mg / kg / day to mice, changes in lymphocytes in the peripheral blood (PB) and bone marrow (BM) were classified into T cells, CD4 T cells, and CD8 T cells, and FACS analysis was performed at 0, 4, 8, 12, 24, and 36 hours after test substance administration. Cell number was measured and expressed as a percentage (% of control) based on 0 time.

[0180] Referring to Figure 8, it was confirmed that administration of 3 mg / kg of compound 1a (crystalline form G) in the peripheral bloodstream (PB) reduced T cells, CD4 T cells, and CD8 T cells to 40.6% / 41.6%, 16.4% / 17.6%, and 5.9% / 9.3% of 0 hour after 4 hours. The decrease was maintained for up to 12 hours and then recovered to 88.9% at 36 hours. Dose dependency was observed in T cells 24 hours after administration, and a dose-dependent reduction effect was confirmed in CD4 T cells and CD8 T cells from 4 to 24 hours after administration.

[0181] In bone marrow (BM), T cell distribution was observed at 135% and 120% 4 hours after administration of 3 mg / kg of compound 1a (crystalline form G), and at 131% and 118% 24 hours after administration. This is believed to be a phenomenon resulting from receptor internalization by compound 1, which inhibits T cell release.

[0182] After administration of 3 mg / kg of compound 1a (crystalline form G), the cell number in T cells decreased from 4 hours onwards, and the inhibitory effect was maintained to some extent for up to 24 hours before recovery. In conclusion, it was confirmed that administration of compound 1a reduced the number of circulating lymphocytes in the bloodstream, resulting in an immunosuppressive effect.

[0183]

[0184] Experimental Example 9: Inhibitory Effect on Rat Immune Cells

[0185] To evaluate the effect of compound 1a on rat immune cells, SD rats were orally administered compound 1a (crystalline form G) at 10 mg / kg / day, and T cells, CD4 T cells, and CD8 T cells in the peripheral bloodstream (PB) and bone marrow (BM) were classified, and FACS analysis was performed at 0, 4, 8, 12, 24, 36, and 48 hours after administration of the test substance. The cell number was measured and expressed as a percentage (% of control) based on 0 time, and the numbers of T cells, CD4 T cells, and CD8 T cells were measured and expressed as % of control based on 0 time.

[0186] Referring to Figure 9, it was confirmed that T cells decreased in the peripheral bloodstream (PB) from 4 hours after administration of compound 1a (crystalline form G). The inhibitory effect was dose-dependent (70%, 80%, 87%), and it was confirmed that the inhibitory effect was maintained for up to 24 hours by administration of 110 mg / kg of the compound. In contrast, in the bone marrow (BM), a tendency of no change or increase was confirmed.

[0187] This study confirmed that compound 1a exhibited immunosuppressive effects by reducing lymphocyte counts in the peripheral bloodstream (PB) after oral administration. Furthermore, a tendency toward either no change or an increase was observed in bone marrow (BM). This effect is believed to be related to the mechanism by which compound 1 inhibits lymphocyte release by acting as a functional antagonist at the S1P receptor present in lymph nodes and bone marrow (BM).

[0188]

[0189] Experimental Example 10: Inhibitory Effect on Inflammatory Bowel Disease Using a Mouse DSS-Induced Model

[0190] The efficacy of compound 1a on inflammatory bowel disease was evaluated using a dextran sulfate sodium (DSS)-induced colitis model. The mouse model was induced to develop inflammatory bowel disease by administering DSS at a concentration of 2.5% to mice through drinking water. The treatment groups consisted of a test group administered compound 1a, a positive control group administered ozanimod or methotrexate (MTX), a vehicle group, and a normal control group, with each group having n=10. In the model in which the above inflammatory bowel disease was induced, compound 1a (crystalline form G) was orally administered once a day for 7 days at doses of 5 and 10 mg / kg, respectively. As a positive control substance, ozanimod was orally administered once a day at 5 mg / kg, and as a positive control substance, MTX (methotrexate) was intraperitoneally administered three times a week at 3 mg / kg.

[0191] Figure 10 shows the disease activity index (DAI) and the area under the curve (AUC) of DSS-induced colitis mice. DAI represents the sum score of weight loss, stool consistency, and intestinal bleeding compared to the initial body weight of the mice. The calculation criteria for DAI are as shown in Table 3 below, and DAI was evaluated on days 0, 1, 2, 3, 4, 5, 6, 7, and 8.

[0192] Score: Weight loss compared to initial body weight; Stool consistency; Intestinal bleeding; 0<1%; Normal; Negative hemoccult; 11-5%; Soft but still formed; Occult blood detected (weak luminol intensity); 26-10%; Soft; Occult blood detected (strong luminol intensity); 31-18%; Very soft; wet; Blood in stool visible to the naked eye; 4>18%; Watery diarrhea; Intestinal bleeding

[0193] Referring to Figure 10, a statistically significant reduction effect was confirmed in all groups administered with 3 mg / kg of MTX, 5 mg / kg of Ozanimod, 5 mg / kg of Compound 1, and 10 mg / kg of Compound 1 compared to the negative control group (Vehicle). In particular, as a result of administering 5 mg / kg of Compound 1a (crystalline form G) and 10 mg / kg of Compound 1a, it was confirmed that clinical indicators such as weight loss, stool concentration, and degree of intestinal bleeding were equivalent or higher than those of Ozanimod, which was previously used as a targeted treatment for ulcerative colitis.

[0194] The above evaluation results were statistically analyzed between the negative control group and the test group or between two test groups, and the significance level was indicated as a p value of 0.05 or less in Student's t-test or Mann Whitney U test for comparison between groups.

[0195] Thus, it was confirmed that compound 1a is a substance that has an inhibitory effect on inflammatory bowel disease.

[0196]

[0197] Experimental Example 11: Evaluation of Effects on the Cardiovascular System

[0198] 1) Evaluation of the effect of compound 1a in HEK293 cells overexpressing the hERG gene

[0199] Compound 1a was applied to HEK-293 cells stably expressing the hERG potassium ion channel by introducing hERG (human Ether-a-go-go Related Gene) to evaluate its effect on hERG channel currents. Compound 1a was set at concentrations of 1, 3, 10, and 30 μM. In addition, on each experimental day, a random cell for which hERG channel currents for the negative control substance or test substance at each concentration had been recorded was treated.

[0200] Referring to Figure 11, the compensated suppression rate (%) of hERG channel currents of compound 1 (groups B to E) at concentrations of 1, 3, 10, and 30 μM were 9.94±1.96, 13.98±4.48, 35.03±12.09, and 82.62±7.31% (n=3), respectively, and the compensated suppression rate (%) of hERG channel currents of the negative control group (group A) was 0±4.12 (n=3). That is, it was confirmed that NCX736 at concentrations of 10 and 30 μM (groups D and E) showed a statistically significant difference compared to the negative control group (group A).

[0201] Under the same conditions, 0.1 μM E-4031, used as a positive control (F group), was treated. The compensated suppression rate (%) of hERG channel currents showed a high value of 92.64 ± 1.66% (n = 5). Based on these results, this assay is considered to be a suitable method for evaluating the effect of compound 1 on hERG channel currents.

[0202] In the evaluation of the effect on hERG channel currents using HEK-293 cells into which the hERG gene was introduced under the above conditions, the compensated suppression rate (%) of hERG channel currents was 82.62±7.31% when the test substance, compound 1a (crystalline form G), was treated at a concentration of up to 30 μM, and K +The ion channel inhibitory activity (IC50) was calculated to be 12.94 μM (Hill coefficient: 1.527). Therefore, it was confirmed that compound 1a is a substance that does not inhibit hERG potassium channel activity and does not cause cardiac abnormalities.

[0203] 2) Confirming the effects on the cardiovascular system using beagle dogs

[0204] Compound 1a was administered orally to four non-anesthetized and unrestrained male beagle dogs implanted with remote transmitters. The heart rates of the four beagle dogs were measured to assess the cardiovascular effects of Compound 1, and the presence of any abnormal symptoms was visually observed.

[0205] In this experiment, the test substance was administered to each of four beagle dogs in four stages. In the first administration stage (compound 10 mg / kg), a 0.5% MC aqueous solution as a control substance was administered, in the second administration stage, 12.5 mg / kg of compound 1a (crystalline form G) was administered, in the third administration stage, 25 mg / kg of compound 1a (crystalline form G) was administered, and in the fourth administration stage, 50 mg / kg of compound 1a (crystalline form G) was administered. The first to fourth administrations were administered at one-week intervals. Additionally, the heart rates of the beagle dogs were measured 0 hours before administration of the experimental substance, and 0.5 hours, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, and 24 hours after administration of the experimental substance.

[0206] Referring to Figure 12, it was confirmed that no change in heart rate was observed even when compound 1a (crystalline form G) was administered at doses of 12.5, 25, and 50 mg / kg.

[0207] In addition, as a result of observing general symptoms in beagle dogs with the naked eye, no abnormal symptoms were observed after administration of compound 1a (crystalline form G) at doses of 12.5, 25, and 50 mg / kg.

[0208] As described above, according to the results of the evaluation of the inhibitory efficacy on inflammatory bowel disease using a mouse DSS-induced model and the results of checking the heart rate and the occurrence of abnormal symptoms visually in beagle dogs administered with compound 1, it was confirmed that the pharmaceutical composition comprising the compound represented by chemical formula 1 according to the present invention, an optical isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient acts as a functional inhibitor for S1PR1 and S1PR4, thereby having a preventive or therapeutic effect on inflammatory bowel disease. In addition, it was confirmed that the pharmaceutical composition according to the present invention acts as a functional inhibitor for S1PR1 and S1PR4 among the subtypes of S1P receptors (S1P1, S1P2, S1P3, S1P4, and S1P5), thereby having a preventive or therapeutic effect on inflammatory bowel disease while not causing cardiovascular disease side effects.

[0209]

[0210] Experimental Example 12: Confirmation of anti-fibrosis efficacy using a mouse kidney fibrosis model.

[0211] The antifibrotic efficacy of compound 1a in renal disease was evaluated using the unilateral ureteral obstruction (UUO) model, a renal fibrosis disease model. After inducing renal fibrosis by ligating one side of the urinary tract in mice, compound 1a at 10, 30, and 90 mg / kg / day and the positive control substance, telmisartan, at 30 mg / kg / day were administered orally once daily for 2 weeks.

[0212] Referring to Figure 13, it was confirmed that renal fibrosis was induced by the vehicle, as the fibrosis area (Sirius red positive area (%)) and renal hydroxyproline were significantly increased compared to the negative control group (sham). Telmisartan, used as a positive control, statistically significantly reduced renal hydroxyproline (p<0.0001). In all groups administered 10, 30, and 90 mg / kg / day of compound 1a (crystalline form G), renal hydroxyproline was statistically significantly reduced (p<0.05, p<0.01, P<0.001), and in particular, it was confirmed that renal hydroxyproline was statistically significantly reduced (p<0.05) in the case of compound 1a 90 mg / kg / day. This confirmed that compound 1 is a substance with a fibrosis inhibitory effect, and it was confirmed that compound 1 exhibits a dose-dependent renal fibrosis inhibitory effect in a mouse renal fibrosis model induced by UUO.

[0213]

[0214] Experimental Example 13: Confirmation of antifibrotic efficacy using a rat mouse model of adenine-induced renal failure.

[0215] The antifibrotic effect of compound 1a (crystalline form G) was evaluated using an adenine-induced chronic kidney disease model. Chronic kidney disease (CKD) was induced in mice by oral administration of 0.5% adenine (in 0.5% CMC) for 4 weeks. After oral administration of compound 1a (crystalline form G) at 10, 30, and 90 mg / kg / day and the positive control substance telmisartan at 10 mg / kg / day for 3 weeks, serum creatinine, serum BUN, renal hydroxyproline were measured, and histopathology was performed. In addition, the tubular-interstitial index value was derived based on the measurement results.

[0216] Biochemical analysis results showed that in the adenine-induced CKD model, the vehicle group significantly increased the serum creatinine level by 1.15±0.25 (mg / dl) and the serum BUN level by 202.3±32.1 (mg / dl) compared to the control group. Compound 1a at 90 mg / kg / day decreased the serum creatinine level by 0.90±0.12 mg / dl compared to the vehicle group, and the serum BUN level decreased by 157.4±32.3 (mg / dl) compared to the vehicle group. In the compound 1a (crystalline form G) 30 mg / kg / day administration group, the renal hydroxyproline level was statistically significantly reduced compared to the control group. Referring to Figure 14, the tubular-interstitial index showed a statistically significant decrease in renal fibrosis in the group administered orally with compound 1a at 90 mg / kg / day and the telmisartan group. In conclusion, the antifibrotic effect of compound 1 was confirmed in the adenine-induced chronic renal fibrosis model.

[0217]

[0218] Experimental Example 14: Confirmation of the efficacy of alopecia areata inhibition using a mouse alopecia areata model.

[0219] The efficacy of compound 1a on alopecia areata was evaluated using a spontaneously occurring alopecia areata model (C3H / HeJ). The C3H / HeJ mice used in the test are animals that naturally progress to alopecia areata as they age. Lymph node cells obtained from C3H / HeJ mice over 20 weeks old with spontaneous alopecia areata were proliferated and injected into 10-16 week old C3H / HeJ mice that were not induced with alopecia areata to induce alopecia areata. After oral administration of compound 1a (crystalline form G) at 30 mg / kg for 12 weeks, the disease-free ratio and AA lesion area were measured (Figs. 15 and 16).

[0220] No significant difference in body weight was observed between the compound 1a administration group and the control group, and alopecia areata was observed later in the compound 1a administration group (100% alopecia areata observed on day 56 in the control group, day 84 in the compound 1a administration group). In addition, in the compound 1a administration group, the area where alopecia areata was observed was statistically significantly smaller than in the control group. (AA lesion area on day 84 - control group: approximately 80%, compound 1a administration group: approximately 10%).

Claims

1. Crystalline Form A of a compound represented by the following chemical formula 1a having diffraction peaks at diffraction angles (2θ±0.2°) of 5.8°, 19.0°, 20.8°, 22.2°, and 26.4° in a powder X-ray diffraction (PXRD) pattern: [Chemical Formula 1a] 2. In the first paragraph, when measuring the IR spectrum, 2924 cm -1 , 2853 cm -1 , 1629 cm -1 , 1533 cm -1 , 1355 cm -1 , 1048 cm -1 , and 808 cm -1 Crystalline form A of a compound represented by chemical formula 1a having a peak at .

3. In the first paragraph, when measuring the Raman spectrum, 28.1 cm -1 , 201.9 cm -1 , 949.9 cm -1 , 1209.7 cm -1 , 1311.4 cm -1 , 1366.8 cm -1 , and 1570.3 cm -1 Crystalline form A of a compound represented by chemical formula 1a having a peak at .

4. Crystalline Form B of a compound represented by the following chemical formula 1a having diffraction peaks at diffraction angles (2θ±0.2°) of 6.4°, 18.6°, 20.7°, 22.4°, and 29.2° in a powder X-ray diffraction pattern (PXRD): [Chemical Formula 1a] 5. In paragraph 4, when measuring the IR spectrum, 2918 cm -1 , 2848 cm -1 , 1629 cm -1 , 1575 cm -1 , 1355 cm -1 , 1045 cm -1 , and 814 cm -1 Crystalline form B of a compound represented by chemical formula 1a having a peak at .

6. In paragraph 4, when measuring the Raman spectrum, 22.3 cm -1 , 259.1 cm -1 , 939.4 cm -1 , 1204.5 cm -1 , 1331.6 cm -1 , 1575.2 cm -1 , and 2813.9 cm -1 Crystalline form B of a compound represented by chemical formula 1a having a peak at .

7. Crystalline Form C of a compound represented by the following chemical formula 1a having diffraction peaks at diffraction angles (2θ±0.2°) of 6.7°, 16.9°, 20.4°, 22.0° 23.5°, 33.0° and 36.4° in a powder X-ray diffraction pattern (PXRD): [Chemical Formula 1a] 8. In paragraph 7, when measuring the IR spectrum, 2920 cm -1 , 2849 cm -1 , 1603 cm -1 , 1554 cm -1 , 1357 cm -1 , 1043 cm -1 , and 807 cm -1 Crystalline form C of a compound represented by the chemical formula 1a having a peak at .

9. In paragraph 7, when measuring the Raman spectrum, 28.1 cm -1 , 115.4 cm -1 , 687.6 cm -1 , 976.3 cm -1 , 1204.5 cm -1 , 1368.8 cm -1 , 1565.4 cm -1 , and 2818.1 cm -1 Crystalline form C of a compound represented by the chemical formula 1a having a peak at .

10. Crystalline Form D of a compound represented by the following chemical formula 1a having diffraction peaks at diffraction angles (2θ±0.2°) of 5.9°, 19.0°, 22.2°, 23.0°, 26.0°, and 26.4° in a powder X-ray diffraction pattern (PXRD): [Chemical Formula 1a] 11. In the 10th paragraph, when measuring the IR spectrum, 2924 cm -1 , 2853 cm -1 , 1629 cm -1 , 1533 cm -1 , 1355 cm -1 , 1048 cm -1 , and 808 cm -1 Crystalline form D of a compound represented by the chemical formula 1a having a peak at .

12. In the 10th paragraph, when measuring the Raman spectrum, 28.1 cm -1 , 201.9 cm -1 , 949.9 cm -1 , 1209.7 cm -1 , 1311.4 cm -1 , 1366.8 cm -1 , and 1570.3 cm -1 Crystalline form D of a compound represented by the chemical formula 1a having a peak at .

13. Crystalline Form E of a compound represented by the following chemical formula 1a having diffraction peaks at diffraction angles (2θ±0.2°) of 18.7°, 20.3°, 21.9°, 22.3°, 26.2°, and 28.6° in a powder X-ray diffraction (PXRD) pattern: [Chemical Formula 1a] 14. In paragraph 13, when measuring the IR spectrum, 2924 cm -1 , 2853 cm -1 , 1639 cm -1 , 1531 cm -1 , 1354 cm -1 , 1048 cm -1 , and 808 cm -1 Crystalline form E of a compound represented by the chemical formula 1a having a peak at .

15. In the 13th paragraph, when measuring the Raman spectrum, 28.1 cm -1 , 201.9 cm -1 , 944.6 cm -1 , 1311.4 cm -1 , 1366.8 cm -1 , and 1570.3 cm -1 Crystalline form E of a compound represented by the chemical formula 1a having a peak at .

16. Crystalline Form F of a compound represented by the following chemical formula 1a having diffraction peaks at diffraction angles (2θ±0.2°) of 18.6°, 19.2°, 20.8°, 25.7°, 29.2°, 31.0°, 32.1°, and 33.9° in a powder X-ray diffraction pattern (PXRD): [Chemical Formula 1a] 17. In paragraph 16, when measuring the IR spectrum, 2918 cm -1 , 2849 cm -1 , 1629 cm -1 , 1575 cm -1 , 1355 cm -1 , 1045 cm -1 , and 814 cm -1 Crystalline form F of a compound represented by the chemical formula 1a having a peak at .

18. In paragraph 16, when measuring the Raman spectrum, 22.3 cm -1 , 259.1 cm -1 , 939.4 cm -1 , 1204.5 cm -1 , 1331.6 cm -1 , 1575.2 cm -1 , and 2813.9 cm -1 Crystalline form F of a compound represented by the chemical formula 1a having a peak at .

19. Crystalline Form G of a compound represented by the following chemical formula 1a having diffraction peaks at diffraction angles (2θ±0.2°) of 8.2°, 18.8°, 20.4°, 22.0°, 24.6°, 26.3°, and 28.7° in a powder X-ray diffraction pattern (PXRD): [Chemical Formula 1a] 20. In paragraph 19, when measuring the IR spectrum, 2924 cm -1 , 2853 cm -1 , 1639 cm -1 , 1531 cm -1 , 1354 cm -1 , 1048 cm -1 , and 808 cm -1 Crystalline form G of a compound represented by chemical formula 1a having a peak at .

21. In paragraph 19, when measuring the Raman spectrum, 28.1 cm -1 , 201.9 cm -1 , 944.6 cm -1 , 1311.4 cm -1 , 1366.8 cm -1 , and 1570.3 cm -1 Crystalline form G of a compound represented by chemical formula 1a having a peak at .

22. In paragraph 16, the crystalline form F of the compound represented by the following chemical formula 1a having a moisture adsorption rate of 0.02% under 90% RH conditions as a result of the DVS evaluation.

23. In paragraph 19, the crystalline form G of the compound represented by the following chemical formula 1a having a moisture adsorption rate of 0.04% under 90% RH conditions as a result of the DVS evaluation.

24. A pharmaceutical composition for the prevention or treatment of multiple sclerosis, ischemic stroke, focal segmental glomerulosclerosis (FSGS), interstitial fibrosis and tubular atrophy (IFTA), inflammatory bowel disease, or alopecia areata (AA), comprising as an active ingredient a crystalline form selected from the group consisting of crystalline form A of paragraph 1, crystalline form B of paragraph 4, crystalline form C of paragraph 7, crystalline form D of paragraph 10, crystalline form E of paragraph 13, crystalline form F of paragraph 16, and crystalline form G of paragraph 19.

25. A method according to claim 24, wherein the inflammatory bowel disease is ulcerative colitis (UC) or Crohn's disease (CD).

26. In claim 24, the pharmaceutical composition is a pharmaceutical composition that does not cause cardiovascular disease side effects.

27. A method for treating multiple sclerosis, ischemic stroke, focal segmental glomerulosclerosis (FSGS), interstitial fibrosis and tubular atrophy (IFTA), inflammatory bowel disease or alopecia areata (AA), comprising administering to a subject a crystalline form selected from the group consisting of crystalline form A of claim 1, crystalline form B of claim 4, crystalline form C of claim 7, crystalline form D of claim 10, crystalline form E of claim 13, crystalline form F of claim 16, and crystalline form G of claim 19, in a pharmaceutically effective amount.

28. A method according to claim 27, wherein the inflammatory bowel disease is ulcerative colitis (UC) or Crohn's disease (CD).

29. In claim 27, the method does not cause cardiovascular disease side effects.

30. Use of a crystalline form selected from the group consisting of crystalline form A of claim 1, crystalline form B of claim 4, crystalline form C of claim 7, crystalline form D of claim 10, crystalline form E of claim 13, crystalline form F of claim 16, and crystalline form G of claim 19 in the manufacture of a medicament for the treatment of multiple sclerosis, ischemic stroke, focal segmental glomerulosclerosis (FSGS), inflammatory bowel disease, interstitial fibrosis and tubular atrophy (IFTA), or alopecia areata (AA).

Citation Information

Patent Citations

  • Novel heteroaromatic ring compound, preparation method thereof, and pharmaceutical composition for use in preventing or treating S1P receptor relating diseases containing the same as an active ingredient

    KR1020170087813A

  • Composition for preventing or treating neurodegenerative disease comprising derivatives of 2-amino-2-(1-dodecyl-1H-1,2,3-triazol-4-yl)propane-1, 3-diol

    KR1020180036318A

  • Novel compounds as receptor modulators with therapeutic utility

    US20120129813A1

  • Substituted 1,2,3-Triazoles as Antitumor Agents

    US20160340321A1

  • KR20230065185A